Readoutin 14d
Jiangsu HengRui Medicine Co., Ltd. — SHR-A1811
Phase 3 primary completion: A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane.
- Date
- Dec 2026
- Type
- Readout
- Indication
- HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane